A randomised,double-blind, placebo-controlled, multi-national, multi-centre, Phase III extension study to assess the long term efficacy, safety and carry-over effect of one of sublingual immunotherapy SLIT administered asllegen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis

Trial Profile

A randomised,double-blind, placebo-controlled, multi-national, multi-centre, Phase III extension study to assess the long term efficacy, safety and carry-over effect of one of sublingual immunotherapy SLIT administered asllegen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 26 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top